Long-term outcomes of low-dose dasatinib in older patients with chronic myeloid leukemia in chronic phase: an extended follow-up of the DAVLEC phase 2 trial - Quiz - MDSpire

Long-term outcomes of low-dose dasatinib in older patients with chronic myeloid leukemia in chronic phase: an extended follow-up of the DAVLEC phase 2 trial

  • By

  • Hiroshi Ureshino

  • Kazunori Murai

  • Takashi Kumagai

  • Tatsuji Mino

  • Kaichi Nishiwaki

  • Satoshi Wakita

  • Tomoharu Takeoka

  • Masayuki Mita

  • Chikashi Yoshida

  • Nobuhiko Uoshima

  • Toshihiro Fukushima

  • Junya Kuroda

  • Takeshi Kondo

  • Masahiro Chiba

  • Takuya Miyazaki

  • Katsuhiro Io

  • Tomoaki Ueda

  • Takaaki Ono

  • Kensuke Usuki

  • Takahiro Yamauchi

  • Katsumichi Fujimaki

  • Takayuki Ikezoe

  • Atsushi Kawaguchi

  • Shinya Kimura

  • May 28, 2026

  • 0 min

Share

Original Source(s)

Long-term outcomes of low-dose dasatinib in older patients with chronic myeloid leukemia in chronic phase: an extended follow-up of the DAVLEC phase 2 trial

  • by Hiroshi Ureshino, Kazunori Murai, Takashi Kumagai, Tatsuji Mino, Kaichi Nishiwaki, Satoshi Wakita, Tomoharu Takeoka, Masayuki Mita, Chikashi Yoshida, Nobuhiko Uoshima, Toshihiro Fukushima, Junya Kuroda, Takeshi Kondo, Masahiro Chiba, Takuya Miyazaki, Katsuhiro Io, Tomoaki Ueda, Takaaki Ono, Kensuke Usuki, Takahiro Yamauchi, Katsumichi Fujimaki, Takayuki Ikezoe, Atsushi Kawaguchi, Shinya Kimura

  • May 28, 2026

Related Content

Use of PCSK9 Inhibitors Among Patients Receiving Immune Checkpoint Inhibitors for Cancer

Predicting preoperative axillary lymph node metastasis to guide surgical decisions in invasive breast cancer

High-grade astrocytoma with piloid features: a case report of comprehensive management